Cresset Asset Management LLC Lowers Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Cresset Asset Management LLC reduced its stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 62.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,400 shares of the company's stock after selling 34,198 shares during the quarter. Cresset Asset Management LLC's holdings in Fresenius Medical Care were worth $462,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $447,000. Northern Trust Corp raised its stake in Fresenius Medical Care by 45.9% in the fourth quarter. Northern Trust Corp now owns 362,190 shares of the company's stock valued at $8,200,000 after purchasing an additional 113,953 shares in the last quarter. Syon Capital LLC purchased a new stake in Fresenius Medical Care in the fourth quarter valued at approximately $262,000. Dimensional Fund Advisors LP raised its stake in Fresenius Medical Care by 86.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 22,820 shares of the company's stock valued at $517,000 after purchasing an additional 10,600 shares in the last quarter. Finally, First Trust Advisors LP purchased a new position in shares of Fresenius Medical Care during the fourth quarter worth approximately $501,000. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Down 0.6%

Shares of NYSE FMS opened at $27.84 on Thursday. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $28.59. The firm's fifty day moving average is $24.80 and its 200 day moving average is $23.56. The company has a market cap of $16.34 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 0.76 and a beta of 0.85.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The company had revenue of $5.54 billion for the quarter, compared to the consensus estimate of $4.71 billion. On average, equities research analysts expect that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Fresenius Medical Care Increases Dividend

The company also recently announced an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be paid a $0.7871 dividend. This represents a dividend yield of 1.9%. This is an increase from Fresenius Medical Care's previous annual dividend of $0.44. The ex-dividend date of this dividend is Friday, May 23rd. Fresenius Medical Care's payout ratio is presently 49.11%.

Analyst Upgrades and Downgrades

Several research firms have commented on FMS. StockNews.com raised shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. Truist Financial lifted their price target on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Monday.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.